citric acid, anhydrous has been researched along with Fatty Liver, Nonalcoholic in 13 studies
Citric Acid: A key intermediate in metabolism. It is an acid compound found in citrus fruits. The salts of citric acid (citrates) can be used as anticoagulants due to their calcium chelating ability.
citric acid : A tricarboxylic acid that is propane-1,2,3-tricarboxylic acid bearing a hydroxy substituent at position 2. It is an important metabolite in the pathway of all aerobic organisms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Nonalcoholic fatty liver disease (NAFLD) is associated with mitochondrial damage." | 1.91 | Circulating Citrate Is Associated with Liver Fibrosis in Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. ( Amjad, W; Connelly, MA; DePaoli, AM; Dullaart, RPF; Garcia, E; Gruppen, EG; Jiang, ZG; Lai, M; Shalaurova, I, 2023) |
| "Nonalcoholic fatty liver disease (NAFLD) and its evolution to inflammatory steatohepatitis (NASH) are the most common causes of chronic liver damage and transplantation that are reaching epidemic proportions due to the upraising incidence of metabolic syndrome, obesity, and diabetes." | 1.56 | Inhibition of the mitochondrial citrate carrier, Slc25a1, reverts steatosis, glucose intolerance, and inflammation in preclinical models of NAFLD/NASH. ( Albanese, C; Avantaggiati, ML; Catalina-Rodriguez, O; Cheema, A; Foley, P; Gadre, S; Giaccone, G; Graham, GT; Kallakury, B; Kasprzyk-Pawelec, A; Mosaoa, R; Parasido, E; Tan, M; Yi, C, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (46.15) | 24.3611 |
| 2020's | 7 (53.85) | 2.80 |
| Authors | Studies |
|---|---|
| Fu, X | 1 |
| Fletcher, JA | 1 |
| Deja, S | 1 |
| Inigo-Vollmer, M | 1 |
| Burgess, SC | 1 |
| Browning, JD | 1 |
| Zhang, L | 1 |
| Hu, W | 2 |
| Qiu, Z | 3 |
| Li, Z | 3 |
| Bian, J | 1 |
| Sun, Q | 2 |
| Guo, Y | 2 |
| Zhang, M | 1 |
| Wang, S | 1 |
| Lei, Y | 1 |
| Meng, H | 1 |
| Li, N | 2 |
| Xu, P | 1 |
| Lin, H | 1 |
| Huang, F | 2 |
| Amjad, W | 1 |
| Shalaurova, I | 1 |
| Garcia, E | 1 |
| Gruppen, EG | 1 |
| Dullaart, RPF | 1 |
| DePaoli, AM | 1 |
| Jiang, ZG | 1 |
| Lai, M | 1 |
| Connelly, MA | 1 |
| Tan, M | 1 |
| Mosaoa, R | 1 |
| Graham, GT | 1 |
| Kasprzyk-Pawelec, A | 1 |
| Gadre, S | 1 |
| Parasido, E | 1 |
| Catalina-Rodriguez, O | 1 |
| Foley, P | 1 |
| Giaccone, G | 1 |
| Cheema, A | 1 |
| Kallakury, B | 1 |
| Albanese, C | 1 |
| Yi, C | 1 |
| Avantaggiati, ML | 1 |
| Niu, Q | 1 |
| Zhuang, Y | 1 |
| Li, X | 1 |
| Liu, J | 1 |
| Branco, JR | 1 |
| Esteves, AM | 1 |
| Leandro, JGB | 1 |
| Demaria, TM | 1 |
| Godoi, V | 1 |
| Marette, A | 1 |
| Valença, HDM | 1 |
| Lanzetti, M | 1 |
| Peyot, ML | 1 |
| Farfari, S | 1 |
| Prentki, M | 1 |
| Zancan, P | 1 |
| Sola-Penna, M | 1 |
| van de Wier, B | 1 |
| Balk, JM | 1 |
| Haenen, GR | 1 |
| Giamouridis, D | 1 |
| Bakker, JA | 1 |
| Bast, BC | 1 |
| den Hartog, GJ | 1 |
| Koek, GH | 1 |
| Bast, A | 1 |
| Iacobazzi, V | 1 |
| Infantino, V | 1 |
| Surapaneni, KM | 2 |
| Priya, VV | 1 |
| Mallika, J | 2 |
| Vishnu Priya, V | 1 |
| Popov, SS | 1 |
| Pashkov, AN | 1 |
| Shul'gin, KK | 1 |
| Brachs, S | 1 |
| Winkel, AF | 1 |
| Tang, H | 1 |
| Birkenfeld, AL | 1 |
| Brunner, B | 1 |
| Jahn-Hofmann, K | 1 |
| Margerie, D | 1 |
| Ruetten, H | 1 |
| Schmoll, D | 1 |
| Spranger, J | 1 |
2 reviews available for citric acid, anhydrous and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
Opportunities and Challenges for Inhibitors Targeting Citrate Transport and Metabolism in Drug Discovery.
Topics: Citrates; Citric Acid; Drug Discovery; Humans; Ion Transport; Male; Non-alcoholic Fatty Liver Diseas | 2023 |
Citrate--new functions for an old metabolite.
Topics: Acetylation; Animals; Citric Acid; Histones; Humans; Inflammation; Insulin; Insulin Secretion; Mitoc | 2014 |
11 other studies available for citric acid, anhydrous and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
Persistent fasting lipogenesis links impaired ketogenesis with citrate synthesis in humans with nonalcoholic fatty liver.
Topics: Citrates; Citric Acid; Fasting; Humans; Ketone Bodies; Lipogenesis; Liver; Non-alcoholic Fatty Liver | 2023 |
Bempedoic Acid Unveils Therapeutic Potential in Non-Alcoholic Fatty Liver Disease: Suppression of the Hepatic PXR-SLC13A5/ACLY Signaling Axis.
Topics: Animals; ATP Citrate (pro-S)-Lyase; Citrates; Citric Acid; Fatty Acids; Liver; Mice; Non-alcoholic F | 2023 |
Circulating Citrate Is Associated with Liver Fibrosis in Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis.
Topics: Adult; Aged; Citrates; Citric Acid; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Humans; Live | 2023 |
Inhibition of the mitochondrial citrate carrier, Slc25a1, reverts steatosis, glucose intolerance, and inflammation in preclinical models of NAFLD/NASH.
Topics: Acetyl Coenzyme A; Animals; Blood Glucose; Carrier Proteins; Cell Polarity; Citric Acid; Diet, High- | 2020 |
Regulation on Citrate Influx and Metabolism through Inhibiting SLC13A5 and ACLY: A Novel Mechanism Mediating the Therapeutic Effects of Curcumin on NAFLD.
Topics: Animals; ATP Citrate (pro-S)-Lyase; Citric Acid; Curcumin; Dicarboxylic Acid Transporters; HEK293 Ce | 2021 |
Dietary citrate acutely induces insulin resistance and markers of liver inflammation in mice.
Topics: Animals; Citric Acid; Diet; Glucose; Glucose Intolerance; Glucose Tolerance Test; Glycogen Synthase | 2021 |
Elevated citrate levels in non-alcoholic fatty liver disease: the potential of citrate to promote radical production.
Topics: Aged; Citric Acid; Fatty Liver; Female; Hep G2 Cells; Humans; Hydrogen Peroxide; Male; Middle Aged; | 2013 |
Pioglitazone, quercetin and hydroxy citric acid effect on cytochrome P450 2E1 (CYP2E1) enzyme levels in experimentally induced non alcoholic steatohepatitis (NASH).
Topics: Animals; Antioxidants; Citric Acid; Cytochrome P-450 CYP2E1; Enzyme Inhibitors; Male; Non-alcoholic | 2014 |
Effect of pioglitazone, quercetin, and hydroxy citric acid on vascular endothelial growth factor messenger RNA (VEGF mRNA) expression in experimentally induced nonalcoholic steatohepatitis (NASH).
Topics: Analysis of Variance; Animals; Antioxidants; Calcium Chelating Agents; Citric Acid; Disease Models, | 2015 |
[EFFECTS OF MELATONIN ON THE ACONITATE HYDRATASE ACTIVITY, CONTENT OF LIPID PEROXIDATION PRODUCTS AND SOME NON-ENZYMATIC ANTIOXIDANTS IN THE BLOOD OF PATIENTS WITH TYPE 2 DIABETES MELLITUS COMPLICATED BY STEATOHEPATITIS].
Topics: Aconitate Hydratase; Adult; Aged; alpha-Tocopherol; Antioxidants; Citric Acid; Diabetes Mellitus, Ty | 2015 |
Inhibition of citrate cotransporter Slc13a5/mINDY by RNAi improves hepatic insulin sensitivity and prevents diet-induced non-alcoholic fatty liver disease in mice.
Topics: Animals; Citrates; Citric Acid; Dicarboxylic Acid Transporters; Diet; Insulin Resistance; Lipid Meta | 2016 |